Citius Oncology

CTOR

Market cap $109M

LYMPHIR now available nationwide CRANFORD, N.J. , Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl).

Citius Oncology's LYMPHIR™ exhibit will be located at Booth #265 LYMPHIR launch on track for Q4 2025 CRANFORD, N.J. , Nov. 25, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it will exhibit at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 6–9, 2025, in Orlando, Florida.

Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launch CRANFORD, N.J. , Nov. 21, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced a deeper collaboration with Verix, a leader in AI-powered commercial optimization technology for the life sciences sector.

McKesson joins leading distribution service providers as authorized U.S. distributor of LYMPHIR CRANFORD, N.J. , Oct. 20, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it has entered into a distribution services agreement with McKesson Corporation (NYSE: MCK), one of the largest pharmaceutical distributors and healthcare services companies in North America.

LD Micro Main Event XIX, October 19-21, 2025 2025 Maxim Growth Summit, October 22-23, 2025 The Think Equity Conference, October 30, 2025 CRANFORD, N.J. , Oct. 17, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) and Citius Oncology, Inc. (Nasdaq: CTOR) today announced that management will be participating in three investor conferences in October 2025.

EVERSANA  to provide integrated commercialization services, enhancing launch readiness and market entry for differentiated Cutaneous T-cell Lymphoma therapy CRANFORD, N.J. , Oct. 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced it has finalized an exclusive agreement with EVERSANA® , a leading provider of global commercialization services, to support the anticipated fourth quarter 2025 U.S. commercialization of LYMPHIR™ (denileukin diftitox-cxdl), Citius Oncology's FDA-approved therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy.

Exclusive relationship through Named Patient Programs establishes footprint in Greece, Cyprus and additional Balkan countries CRANFORD, N.J. , Oct. 7, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies today announced it is actively engaging with regional distribution partners to make LYMPHIR™ (denileukin diftitox-cxdl) available to eligible patients through country-specific Named Patient Programs (NPPs) in Europe, South America and the Middle East.

CRANFORD, N.J. , Sept. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced the closing of its previously announced registered direct offering and concurrent private placement of an aggregate of 5,142,858 shares of common stock and unregistered warrants to purchase up to an aggregate of 5,142,858 shares of common stock.

CRANFORD, N.J. , Sept. 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,142,858 shares of common stock in a registered direct offering.

Proprietary model informs targeted sales and marketing strategies with feedback loop that augments precision and impact of targeting and engagement CRANFORD, N.J. , Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has deployed an innovative AI platform to support its commercial team with advanced data analytics and insights ahead of the anticipated launch of LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma (CTCL).